Tomohide Takaya

Dr. Tomohide Takaya

Faculty of Agriculture, Shinshu University, Ina, Nagano, Japan
orcid
Associate Professor, Faculty of Agriculture, Shinshu Univers...

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2008 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RTRieko Takanabe
Rieko Takanabe
KOKoh Ono
Koh Ono
YAYukiko Abe
Yukiko Abe
Tomohide TakayaTomohide Takaya
Tomohide Takaya
THTakahiro Horie
Takahiro Horie
KHKoji Hasegawa
Koji Hasegawa

1 February 2008 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
TMTatsuya Morimoto
Tatsuya Morimoto
YSYoichi Sunagawa
Yoichi Sunagawa
TKTeruhisa Kawamura
Teruhisa Kawamura
Tomohide TakayaTomohide Takaya
Tomohide Takaya
HWHiromichi Wada
Hiromichi Wada
KHKoji Hasegawa
Koji Hasegawa
Hemodynamic overload in the heart can trigger maladaptive hypertrophy of cardiomyocytes. A key signaling event in this process is nuclear acetylation by histone deacetylases and p300, an intrinsic histone acetyltransferase (HAT). It has been previously shown that curcumin, a polyphenol responsible for the yellow color of the spice turmeric, possesses HAT inhibitory activity with specificity for the p300/CREB-binding protein. We found that curcumin inhibited the hypertrophy-induced acetylation and DNA-binding abilities of GATA4, a hypertrophy-responsive transcription factor, in rat cardiomyocytes. Curcumin also disrupted the p300/GATA4 complex and repressed agonist- and p300-induced hypertrophic responses in these cells. Both the acetylated form of GATA4 and the relative levels of the p300/GATA4 complex markedly increased in rat hypertensive hearts in vivo. The effects of curcumin were examined in vivo in 2 different heart failure models: hypertensive heart disease in salt-sensitive Dahl rats and surgically induced myocardial infarction in rats. In both models, curcumin prevented deterioration of systolic function and heart failure–induced increases in both myocardial wall thickness and diameter. From these results, we conclude that inhibition of p300 HAT activity by the nontoxic dietary compound curcumin may provide a novel therapeutic strategy for heart failure in humans.

2 August 2011 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
RYRyo Yoshimoto
Ryo Yoshimoto
YFYoshiko Fujita
Yoshiko Fujita
AKAkemi Kakino
Akemi Kakino
SIShin Iwamoto
Shin Iwamoto
Tomohide TakayaTomohide Takaya
Tomohide Takaya
TSTatsuya Sawamura
Tatsuya Sawamura
LOX-1 is an endothelial receptor for oxidized low-density lipoprotein (oxLDL), a key molecule in the pathogenesis of atherosclerosis.The basal expression of LOX-1 is low but highly induced under the influence of proinflammatory and prooxidative stimuli in vascular endothelial cells, smooth muscle cells, macrophages, platelets and cardiomyocytes. Multiple lines of in vitro and in vivo studies have provided compelling evidence that LOX-1 promotes endothelial dysfunction and atherogenesis induced by oxLDL. The roles of LOX-1 in the development of atherosclerosis, however, are not simple as it had been considered. Evidence has been accumulating that LOX-1 recognizes not only oxLDL but other atherogenic lipoproteins, platelets, leukocytes and CRP. As results, LOX-1 not only mediates endothelial dysfunction but contributes to atherosclerotic plaque formation, thrombogenesis, leukocyte infiltration and myocardial infarction, which determine mortality and morbidity from atherosclerosis. Moreover, our recent epidemiological study has highlighted the involvement of LOX-1 in human cardiovascular diseases. Further understandings of LOX-1 and its ligands as well as its versatile functions will direct us to ways to find novel diagnostic and therapeutic approaches to cardiovascular disease.

1 January 2009 in Circulation Journal
Verified
Journal Article
Open access
PDF file
Tomohide TakayaTomohide Takaya
Tomohide Takaya
KOKoh Ono
Koh Ono
TKTeruhisa Kawamura
Teruhisa Kawamura
RTRieko Takanabe
Rieko Takanabe
SKShinji Kaichi
Shinji Kaichi
KHKoji Hasegawa
Koji Hasegawa
Background: MicroRNAs (miRNAs) regulate various biological processes through inhibiting the translation of RNA transcripts. Although miRNA-1 (miR-1) and miRNA-133 (miR-133) are abundantly expressed in the adult heart and involved in cardiac hypertrophy, the roles of these miRNAs in spontaneous myocardial differentiation are unknown. Methods and Results: The levels of miR-1 and miR-133 in mouse embryonic stem (ES) cells were increased during spontaneous differentiation by 2-dimensional culture, but reduced during forced myocardial differentiation by a histone deacetylase inhibitor, trichostatin A. The overexpression of miR-1 or miR-133 by lentiviral infection reduced the expression of a cardiac-specific gene, Nkx2.5, during differentiation of ES cells. In addition, miR-1 also inhibited α-myosin heavy chain expression. The results of luciferase assays revealed that miR-1 recognizes and targets the 3' untranslated region of cyclin-dependent kinase-9 (Cdk9) in ES cells. Overexpression of miR-1 decreased the protein amounts of Cdk9 without affecting the mRNA levels, indicating that miR-1 post-transcriptionally inhibits Cdk9 translation. Conclusions: miR-1 and miR-133 may play significant roles in the myocardial differentiation of mouse ES cells, and Cdk9 may be involved in this process as a target of miR-1. (Circ J 2009; 73: 1492 - 1497)

1 April 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Tomohide TakayaTomohide Takaya
Tomohide Takaya
TKTeruhisa Kawamura
Teruhisa Kawamura
TMTatsuya Morimoto
Tatsuya Morimoto
KOKoh Ono
Koh Ono
TKToru Kita
Toru Kita
KHKoji Hasegawa
Koji Hasegawa
A zinc finger protein, GATA4, is one of the hypertrophy-responsive transcription factors and increases its DNA binding and transcriptional activities in response to hypertrophic stimuli in cardiac myocytes. Activation of GATA4 during this process is mediated, in part, through acetylation by intrinsic histone acetyltransferases such as a transcriptional coactivator p300. However, p300-targeted acetylated sites of GATA4 during myocardial cell hypertrophy have not been identified. By mutational analysis, we showed that 4 lysine residues located between amino acids 311 and 322 are required for synergistic activation of atrial natriuretic factor and endothelin-1 promoters by GATA4 and p300. A tetra-mutant GATA4, in which these 4 lysine residues were simultaneously mutated, retained the ability to localize in nuclei and to interact with cofactors including FOG-2, GATA6, and p300 but lacked p300-induced acetylation, DNA binding, and transcriptional activities. Furthermore, coexpression of the tetra-mutant GATA4 with wild-type GATA4 impaired the p300-induced acetylation, DNA binding, and transcriptional activities of the wild type. When we expressed the tetra-mutant GATA4 in neonatal rat cardiac myocytes using a lentivirus vector, this mutant suppressed phenylephrine-induced increases in cell size, protein synthesis, and expression of hypertrophy-responsive genes. However, its expression did not affect the basal state. Thus, we have identified the most critical lysine residues acting as p300-mediated acetylation targets in GATA4 during hypertrophic responses in cardiac myocytes. The results also demonstrate that GATA4 with simultaneous mutation of these sites specifically suppresses hypertrophic responses as a dominant-negative form, providing further evidence for the acetylation of GATA4 as one of critical nuclear events in myocardial cell hypertrophy.

1 January 2011 in Circulation Journal
Verified
Journal Article
Open access
PDF file
YSYoichi Sunagawa
Yoichi Sunagawa
TMTatsuya Morimoto
Tatsuya Morimoto
HWHiromichi Wada
Hiromichi Wada
Tomohide TakayaTomohide Takaya
Tomohide Takaya
YKYasufumi Katanasaka
Yasufumi Katanasaka
KHKoji Hasegawa
Koji Hasegawa
Background: A natural p300-specific histone acetyltransferase (HAT) inhibitor, curcumin, may have therapeutic potential for heart failure. However, it is unclear whether curcumin exhibits beneficial additive or synergistic effects on conventional therapy with angiotensin-converting enzyme inhibitors (ACEIs). Methods and Results: Rats were subjected to a sham operation or left coronary artery ligation. One week later, 34 rats with a moderate sized myocardial infarction (MI) were randomly assigned to 4 groups: solvents as control (n=8), enalapril (an ACEI, 10mg·kg-1·day-1) alone (n=8), curcumin (50mg·kg-1·day-1) alone (n=9) and enalapril plus curcumin (n=9). Daily oral treatment was repeated and continued for 6 weeks. Echocardiographic data were similar among the 4 groups before treatment. After treatment, left ventricular (LV) fractional shortening (FS) was significantly higher in the enalapril (29.0±1.9%) and curcumin (30.8±1.7%) groups than in the vehicle group (19.7±1.6%). Notably, LVFS further increased in the enalapril/curcumin combination group (34.4±1.8%). Histologically, cardiomyocyte diameter in the non-infarct area was smaller in the enalapril/curcumin combination group than in the enalapril group. Perivascular fibrosis was significantly reduced in the enalapril/curcumin group compared with the curcumin group. Conclusions: A natural non-toxic dietary compound, curcumin, combined with an ACEI exerts beneficial effects on post-MI LV systolic function in rats. (Circ J 2011; 75: 2151-2159)